Azitra, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Azitra, Inc. (AZTR) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $11.40 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-12
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $11.40K, a 28.86% decline year-over-year.
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $6.15K, a 79.77% decline year-over-year.
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $4.17K, a 97.10% decline year-over-year.
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $16.03K, a 53.08% decline year-over-year.
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $62.74K, a 74.40% decline from fiscal 2024.
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $245.05K, a 61.75% increase from fiscal 2023.
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $151.50K, a 17.87% decline from fiscal 2022.
- Azitra, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $184.47K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.40K 10-Q · filed 2026-08-12 | $17.55K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $6.15K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $62.74K 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $4.17K 10-Q · filed 2025-11-12 | $20.20K derived: sum of 2 quarters · filed 2026-08-12 | $50.60K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $16.03K 10-Q · filed 2026-08-12 | $46.43K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $30.40K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $245.05K 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $143.53K 10-Q · filed 2025-11-12 | $177.70K derived: sum of 2 quarters · filed 2025-11-12 | $211.88K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $34.17K 10-Q · filed 2025-11-12 | $68.34K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $34.17K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $151.50K 10-K · filed 2025-02-24 | |||
| 2023-09-30 | $39.07K 10-Q · filed 2024-11-12 | $77.87K derived: sum of 2 quarters · filed 2024-11-12 | $116.66K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $38.79K 10-Q · filed 2024-11-12 | $77.59K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $38.79K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $184.47K 10-K · filed 2024-03-15 | |||
| 2022-09-30 | $44.33K 10-Q · filed 2023-11-14 | $98.16K derived: sum of 2 quarters · filed 2023-11-14 | $155.14K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $53.83K 10-Q · filed 2023-11-14 | $110.81K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $56.98K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |